The results of this systematic review and meta-analysis indicate that there are substantial differences in [18F]FDG uptake expressed as SUVmax of the primary tumour between negative and positive IHC expression of ER, PR, HER2, Ki-67, and between clinical subtypes based on these markers. This evidence concerns the gene ERBB2 and neoplasm.